Prasugrel approved by the FDA: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
July 10 by C. Michael Gibson, M.S., M.D. (click [[C. Michael Gibson|here]] for Dr. Gibson's disclosures) | July 10 by C. Michael Gibson, M.S., M.D. (click [[C. Michael Gibson|here]] for Dr. Gibson's disclosures) | ||
The Food and Drug Administration announced today that [[Prasugrel]] (which will be sold under the name Effient) is now approved for clinical use. The drug's label indicates that the drug is effective in reducing the risk of stroke and heart attack in patients undergoing percutaneous intervention and will carry a black label warning regarding an increased risk of potentially fatal bleeding. A panel convened by the FDA had previously voted 9-0 in a recommendation for approval on February 3rd, 2009. | The Food and Drug Administration announced today that [[Prasugrel]] (which will be sold under the name Effient) is now approved for clinical use. The drug's label indicates that the drug is effective in reducing the risk of stroke and heart attack in patients undergoing percutaneous intervention and will carry a black label warning regarding an increased risk of potentially fatal bleeding. A panel convened by the FDA had previously voted 9-0 in a recommendation for approval on February 3rd, 2009. | ||
It is notable that there are two approved maintenance doses: 10 mg which was studied in the Triton TIMI 38 trial, and a reduced dose of 5 mg. | It is notable that there are two approved maintenance doses: 10 mg which was studied in the Triton TIMI 38 trial, and a reduced dose of 5 mg that may be more suitable in patients at an increased risk of bleeding. | ||
Although concerns had been expressed regarding an excess risk of cancer in the Prasugrel arm, Deputy Director of the Cardiovascular & Renal Products division Ellis Unger has stated that there is no increase in the relative risk of cancer for prasugrel over clopidogrel if those patients with gastrointestinal bleeding are excluded from the analysis. | |||
The drug is marketed by both Eli Lilly and Daiichi-Sankyo. | The drug is marketed by both Eli Lilly and Daiichi-Sankyo. | ||
Revision as of 20:57, 10 July 2009
July 10 by C. Michael Gibson, M.S., M.D. (click here for Dr. Gibson's disclosures)
The Food and Drug Administration announced today that Prasugrel (which will be sold under the name Effient) is now approved for clinical use. The drug's label indicates that the drug is effective in reducing the risk of stroke and heart attack in patients undergoing percutaneous intervention and will carry a black label warning regarding an increased risk of potentially fatal bleeding. A panel convened by the FDA had previously voted 9-0 in a recommendation for approval on February 3rd, 2009.
It is notable that there are two approved maintenance doses: 10 mg which was studied in the Triton TIMI 38 trial, and a reduced dose of 5 mg that may be more suitable in patients at an increased risk of bleeding.
Although concerns had been expressed regarding an excess risk of cancer in the Prasugrel arm, Deputy Director of the Cardiovascular & Renal Products division Ellis Unger has stated that there is no increase in the relative risk of cancer for prasugrel over clopidogrel if those patients with gastrointestinal bleeding are excluded from the analysis.
The drug is marketed by both Eli Lilly and Daiichi-Sankyo.